COMMUNIQUÉS West-GlobeNewswire

Arch Biopartners Forms New Subsidiary to Pursue a Phase I Trial in Australia for Metablok (LSALT Peptide)
11/12/2018
TORONTO, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (Arch or the Company) (TSX Venture: ARCH and OTCQB: ACHFF) today announced it has formed a 100% owned subsidiary in Australia, named Arch Clinical Pty [...]
Rafael Pharmaceuticals Announces Initiation of Pivotal Phase 3 Trial (AVENGER 500) of CPI-613 (devimistat) in Combination with Modified FOLFIRINOX as First Line Treatment for Patients with Metastatic Pancreatic Cancer
11/12/2018
Interim analysis expected as early as Q2 2020 Newark, NJ, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (Rafael), a leader in the growing field of cancer metabolism-based therapeutics, today announced [...]
NexImmune Granted Key US Patent for Core E+E Technology
11/12/2018
GAITHERSBURG, Md., Dec. 11, 2018 (GLOBE NEWSWIRE) -- NexImmune, an emerging leader in the field of antigen-directed immunotherapy, today announced that the United States Patent and Trademark Office has issued a new [...]
ImmuCell Announces USDA Approval of Dual-Force™ First Defense®
11/12/2018
PORTLAND, Maine, Dec. 11, 2018 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and [...]
Shockwave Announces collaboration With Abiomed on Physician Training
11/12/2018
Abiomed Invests $15 Million in Shockwave SANTA CLARA, Calif., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Shockwave Medical, a pioneer in the development and commercialization of intravascular lithotripsy to treat complex [...]
Operation Hat Trick Donates $10,000 to SoldierStrong
11/12/2018
Nonprofit Organizations Share Purpose of Supporting Injured Veterans STAMFORD, Conn. and HAMPTON, N.H., Dec. 11, 2018 (GLOBE NEWSWIRE) -- SoldierStrong, a nonprofit organization dedicated to providing advanced medical [...]
Fibrocell Receives $900,000 Investment from EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation
11/12/2018
Funding to Help Further Clinical Development of FCX-007 Gene Therapy for Treatment of Recessive Dystrophic Epidermolysis Bullosa EXTON, Pa., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ: FCSC), a [...]
HealthLynked to Attend the 2019 HIMSS Global Conference & Exhibition
11/12/2018
NAPLES, Fla., Dec. 11, 2018 (GLOBE NEWSWIRE) -- HealthLynked Corp. (OTCQB: HLYK) today announced that the Company will be attending the HIMSS Global Conference & Exhibition ( Healthcare Information and Management [...]
eFFECTOR Initiates Dosing in Phase 2 Trial of Tomivosertib (eFT508) in Advanced Castrate-Resistant Prostate Cancer (CRPC)
11/12/2018
SAN DIEGO, Dec. 11, 2018 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., (eFFECTOR), a leader in the development of selective translation regulators (STRs) for the treatment of cancer, announced today that it has dosed [...]
Comfort Launch by Vergence Naturals Exceeds Expectations
11/12/2018
VANCOUVER, British Columbia, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Abattis Bioceuticals Corp. (the “ Company ” or “ Abattis ”) (CSE:ATT) (OTC:ATTBF) is pleased to provide an update on the recent soft-launch of its [...]
CLS Holdings USA, Inc Announces Receipt for Final Prospectus From Ontario Securities Commission and Conditional Approval to List on the Canadian Securities Exchange
11/12/2018
LAS VEGAS, Dec. 11, 2018 (GLOBE NEWSWIRE) -- CLS Holdings USA, Inc. (OTCQB: CLSH) “ CLS ,” a diversified cannabis company operating as Cannabis Life Sciences and an integrated cannabis producer and retailer in Nevada [...]
Novan to Present Data from SB414 Phase 1b Atopic Dermatitis Clinical Trial at 3rd Inflammatory Skin Disease Summit
11/12/2018
Clinical efficacy, as measured by EASI (Eczema Area and Severity Index) changes, was numerically greater for SB414 treated groups compared to vehicle Strong anti-pruritic (itch) effect as measured by improvement on the [...]
T1D Exchange Names New Board Members
11/12/2018
Expanded Board to Strengthen Type 1 Diabetes Expertise and Philanthropic Reach BOSTON, Dec. 11, 2018 (GLOBE NEWSWIRE) -- T1D Exchange , a nonprofit, research organization dedicated to accelerating therapies and [...]
Intensity Therapeutics Strengthens Intellectual Property Portfolio with Issuance of Several New Patents in Asia and Australia
11/12/2018
Patents granted in five countries protect the Company’s novel technology and intratumoral, immune cell-activating product candidates, including INT230-6 WESTPORT, Conn., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Intensity [...]
Helius Medical Technologies, Inc. Announces Exercise of Underwriters’ Overallotment Option
11/12/2018
NEWTOWN, Pa., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”) announced today that the underwriters of its previously announced public offering of [...]
3rd Quarter Results
11/12/2018
Summit Therapeutics plc (‘Summit’, the ‘Company’ or the ‘Group’) Summit Therapeutics Reports Financial Results for the Third Quarter and Nine Months Ended 31 October 2018 and Operational Progress Continued Momentum in [...]
Griffon Pharmaceuticals appoints Dr. Marc Cluzel to Board of Directors
11/12/2018
MONTREAL, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Montreal-based biopharmaceutical company Griffon Pharmaceuticals Inc. (“Griffon”) announced today that Marc Cluzel, MD, PhD, joins the company’s Board of Directors. Dr. Cluzel [...]
Athenex Announces Positive Second Cohort Results of Oraxol-plus-Ramucirumab Phase 1b Clinical Trial in Gastric Cancer
11/12/2018
BUFFALO, N.Y., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc., a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today [...]
Intra-Cellular Therapies Announces FDA Acceptance of New Drug Application for Lumateperone for the Treatment of Schizophrenia
11/12/2018
NEW YORK, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today [...]

Pages